A Novel Oxo‐Palmatine Derivative 2q as Potent Reversal Agents Against Alzheimer's Disease
Drug Development Research · 2025
DOI: 10.1002/ddr.70073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Shuo Pang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Laboratory of Neurological Disorders and Brain Cognition, Beijing Pediatric Research Institute, Beijing Children's Hospital, National Center for …. Hauptthemen laut MEDLINE: Alzheimer Disease, Berberine Alkaloids, Neuroprotective Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: This study was supported by the Beijing Natural Science Foundation (grant no. 7244343), National Natural Science Foundation of China (grant no. 82401383, 82471….
Themen: Demenz
Abstract (Originalsprache)
Palmatine (PAL), as an active ingredient in traditional Chinese medicine, had been demonstrated efficacy in ameliorating the manifestations of AD. Our research group has previously designed and synthesized the novel oxo‐PAL derivative 2q and found that it has exhibited notable neuroprotective properties. However, compound 2q therapeutic impact on AD remains uncertain. In the current investigation, our findings demonstrated that compound 2q displayed significant anti‐AβOs activity in vitro by using xCELLigence analysis, and showed a high likelihood of crossing the blood‐brain barrier. Furthermore, administration of compound 2q yielded a notable amelioration in Aβ accumulation and hyperphosphorylation of Tau in 3×Tg mice. Additionally, it was observed that compound 2q potentially enhanced the pathological characteristics of AD by targeting Potassium/Sodium Hyperpolarization‐Activated Cyclic Nucleotide‐Gated Channel 2 (HCN2). In conclusion, compound 2q emerged as a promising candidate for AD treatment, as it effectively restored AD‐associated pathological impairments. Furthermore, it has been identified as a potential target of HCN2, thereby offering novel avenues for the development of treatments for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Laboratory of Neurological Disorders and Brain Cognition, Beijing Pediatric Research Institute, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
- Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
- Department of Neuropathology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Key Laboratory of Human Disease Comparative Medicine, National Health Commission of China (NHC), Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chi…
- Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
ORCID-Profile: Shuo Pang, Zhuo Li, Songqiao Fan, Jun Chen
Förderung
- This study was supported by the Beijing Natural Science Foundation (grant no. 7244343), National Natural Science Foundation of China (grant no. 82401383, 82471…
Zitieren
APA
Pang, S., Li, Z., Liu, A., Luo, Z. H., Yin, H., Fan, S., Shi, J., Liu, N., Pan, S., Yang, Y. J., Zhang, G. J., & Chen, J. (2025). A Novel Oxo‐Palmatine Derivative 2q as Potent Reversal Agents Against Alzheimer's Disease. Drug Development Research. https://doi.org/10.1002/ddr.70073
Vancouver
Pang S, Li Z, Liu A, Luo ZH, Yin H, Fan S, et al. A Novel Oxo‐Palmatine Derivative 2q as Potent Reversal Agents Against Alzheimer's Disease. Drug Development Research. 2025. doi:10.1002/ddr.70073
BibTeX
@article{Pang2025,
author = {Pang, Shuo and Li, Zhuo and Liu, Ao and Luo, Zhuo-Hui and Yin, Heqing and Fan, Songqiao and Shi, Junjie and Liu, Ning and Pan, Shuo and Yang, Ya-Jun and Zhang, Guo-Jun and Chen, Jun},
title = {A Novel Oxo‐Palmatine Derivative 2q as Potent Reversal Agents Against Alzheimer's Disease},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70073}
}
EUVIMED